carbamic acid 3- (4- ((4- amino- 5- chloro- 2- methoxybenzoylamino)methyl)piperidin- 1- yl)- 1- (4- fluorophenyl)propyl ester

04/01/2015 - "We investigated the safety and effects of YKP10811 on GI and colonic transit and bowel movements (BMs) in patients with functional constipation in a randomized, double-blind, placebo-controlled study. "
04/01/2015 - "A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation."
04/01/2015 - "Patients with functional constipation, based on the Rome III criteria, were assigned randomly to groups given YKP10811 10 mg (n = 15), 20 mg (n = 16), 30 mg (n = 15), or placebo (n = 11) daily for 8 days. "
04/01/2015 - "YKP10811, a selective agonist of the serotonin receptor 5-hydroxytryptamine-4, accelerates GI and colonic transit and improves bowel functions in patients with functional constipation, compared with placebo. "

03/01/2017 - "YKP10811 may have a therapeutic potential for gastroparesis."

12/01/2014 - "YKP10811exhibits antinociceptive activity in inflammation and acute stress-induced colonic hypersensitivity through 5-HT4 receptors but unlike tegaserod, YKP10811 maintains its activity after repeated administrations and may represent a new candidate to treat IBS-C patients."
12/01/2014 - "Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation."

12/01/2014 - "YKP10811 attenuated acute PRS-induced but not chronic WAS-induced colonic hypersensitivity. "
12/01/2014 - "We tested a possible pharmacological tachyphylaxis of YKP10811 in TNBS-induced hypersensitivity. "
12/01/2014 - "In addition, YKP10811 but not tegaserod reduced TNBS-induced colorectal hypersensitivity after 7 days of treatment. "
12/01/2014 - "This work was aimed to evaluate the influence of YKP10811, a new potent 5-HT4 receptor partial agonist, on rat models of colorectal hypersensitivity to distension. "
12/01/2014 - "YKP10811exhibits antinociceptive activity in inflammation and acute stress-induced colonic hypersensitivity through 5-HT4 receptors but unlike tegaserod, YKP10811 maintains its activity after repeated administrations and may represent a new candidate to treat IBS-C patients."

03/01/2017 - "(i) High-dose YKP10811 (30 mg/kg) accelerated liquid gastric emptying from 15 to 90 min without inducing adverse events or cardiac dysrhythmia. "